Asset Details
Do you wish to reserve the book?
FAM46C Expression Sensitizes Multiple Myeloma Cells to PF-543-Induced Cytotoxicity
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
FAM46C Expression Sensitizes Multiple Myeloma Cells to PF-543-Induced Cytotoxicity
Do you wish to request the book?
FAM46C Expression Sensitizes Multiple Myeloma Cells to PF-543-Induced Cytotoxicity
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
FAM46C Expression Sensitizes Multiple Myeloma Cells to PF-543-Induced Cytotoxicity
2025
Overview
FAM46C is a tumor suppressor initially identified in multiple myeloma (MM) but increasingly recognized for its role also in other cancers. Despite its significance, studies exploring the therapeutic potential of FAM46C in combination with targeted treatments remain limited. Sphingosine kinases (SphK1 and SphK2) are key regulators of sphingolipid signaling, a pathway essential for maintaining cell structure and function but frequently deregulated in tumors, making them promising targets for cancer therapy. Preliminary work from our laboratory showed that FAM46C expression synergizes with administration of SKI-I, a pan-inhibitor of sphingosine kinases. In this study, we focused specifically on SphK1, the sphingosine kinase predominantly implicated in cancer and investigated the combinatorial effect of forced FAM46C expression and treatment with PF-543, a selective SphK1 inhibitor. We found that FAM46C overexpression enhances, whereas its downregulation reduces, the cytotoxic efficacy of PF-543 in MM cell lines. Using an in vivo xenograft model, we further validated these findings, showing that FAM46C-expressing MM tumors are indeed sensitive to PF-543 while tumors harboring the D90G loss-of-function variant of FAM46C are not. Overall, our results uncover a novel synergistic interaction between FAM46C expression and SphK1 inhibition, highlighting a promising therapeutic strategy for MM treatment.
Publisher
MDPI AG,MDPI
Subject
Adamantane - analogs & derivatives
/ Animals
/ Cancer
/ Cloning
/ Gene Expression Regulation, Neoplastic - drug effects
/ Humans
/ Kinases
/ Mice
/ Multiple Myeloma - drug therapy
/ Multiple Myeloma - metabolism
/ Multiple Myeloma - pathology
/ myeloma
/ PF-543
/ Phosphotransferases (Alcohol Group Acceptor) - antagonists & inhibitors
/ Phosphotransferases (Alcohol Group Acceptor) - genetics
/ Phosphotransferases (Alcohol Group Acceptor) - metabolism
/ Proteins
/ Structure-function relationships
/ TENT5C
/ Tumors
